InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (6 ops.)
Insider track record
CEODisclosed buys
0
Disclosed sells
6
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Browse the complete record of transactions filed by Mattsson Jan, Executive. Insider active across 1 company, notably Albireo Pharma, INC.. Cumulatively, 10 disclosures have been published. Split: 0 buy · 6 sells. Total volume traded: €166k. Activity tracked since 18 January 2022. The latest transaction was filed on 19 January 2023 (Attribution). Regulator: SEC (Form 4). The full history is openly available.
Companies and markets linked to Mattsson Jan
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations10 total
35,524 sharesCommon StockSEC:0001209191-23-014736:0
55,000 shares0Common StockSEC:0001209191-23-005337:0
55,000 shares0Common StockSEC:0001209191-23-004952:0
197 shares@ US$43.804.3% of flowCommon StockSEC:0001209191-23-004455:0
3,088 shares@ US$43.8068.2% of flowCommon StockSEC:0001209191-23-004222:0
202 shares@ US$19.57642.2% of flowCommon StockSEC:0001209191-22-054489:0
205 shares@ US$24.67522.7% of flowCommon StockSEC:0001209191-22-043112:0
200 shares@ US$32.924714.6% of flowCommon StockSEC:0001209191-22-025526:0
808 shares@ US$24.882242.7% of flowCommon StockSEC:0001209191-22-004803:0
21,600 shares0Common StockSEC:0001209191-22-004068:0
10 of 10 declarations
About Mattsson Jan
Jan Mattsson is the Chief Scientific Officer at Albireo Pharma, Inc. In this role, he is responsible for the scientific direction and innovation within the company. His expertise in the pharmaceutical field contributes to the development of new treatments and the advancement of the company's research goals.
